Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 1.00 |
| ▸ | DRD3 | P35462 | 15/20 | 1.00 |
| ▸ | DRD4 | P21917 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | FYN | P06241 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930123 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL29460204 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL29448457 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL7568447 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| Bromide SCHEMBL4204027 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL7499793 | 0.94 | DRD2 (0.89) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL28381701 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL28381702 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL10074634 | 0.88 | DRD2 (0.79) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL9585366 | 0.88 | DRD2 (0.85) | DRD2DRD3DRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| US-20220072042-A1 | METHODS FOR IMPROVED IMMUNOTHERAPY | LEVITE MIA (IL) | 2022-03-10 | — | — | US | claimed |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SPRIASO LLC (US) | 2018-06-28 | — | — | US | claimed |
| WO-2016014242-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC (US) | 2016-01-28 | — | — | WO | claimed |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC | 2016-01-21 | — | — | US | claimed |
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SPRIASO LLC | 2016-01-21 | — | — | US | claimed |
| EP-2049129-B1 | CATECHOLAMINE RECEPTOR MODULATION | YEDA RES & DEV (IL) | 2013-06-12 | — | — | EP | claimed |
| US-8241903-B2 | Catecholamine receptor modulation | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2012-08-14 | — | — | US | claimed |
| US-20120164139-A1 | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-06-28 | — | — | US | claimed |
| US-20100099669-A1 | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders | PASRICHA PANKAJ JAY | 2010-04-22 | — | — | US | claimed |
| US-20090176705-A1 | MODULAR PLATFORM FOR TARGETED THERAPEUTIC DELIVERY | WASHINGTON UNIVERSITY (US) | 2009-07-09 | — | — | US | claimed |
| US-20060116350-A1 | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2006-06-01 | — | — | US | claimed |
| WO-2004050065-A1 | INTRAOCULAR DELIVERY COMPOSITIONS AND METHODS | BIOSANTE PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20030185892-A1 | Intraocular delivery compositions and methods | BIOSANTE PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | claimed |
| JP-10279404-A | — | — | None | — | — | JP | disclosed |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12611412-B2 | Targeting the TLK1/NEK1 axis in prostate cancer | BOARD OF SUPERVISORS OF LOUISANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2026-04-28 | — | — | US | disclosed |
| WO-1990015047-A1 | THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
| WO-1990007490-A1 | HALO SUBSTITUTED AMINOTETRALINS | THE UPJOHN COMPANY (US) | 1990-07-12 | — | — | WO | disclosed |
| WO-1989009050-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1989-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SLC7A1, CYP2D6, SLC19A1 | DRD2 1496/4885DRD3 1430/4885DRD4 1516/4885 |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SLC7A1, CYP2D6, CYP3A7 | DRD2 1602/4885DRD3 1564/4885DRD4 1742/4885 |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | WNT3, TRPV3, ADRB3 | DRD2 1584/4885DRD3 253/4885DRD4 2066/4885 |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SLC7A1, CYP2D6, CYP3A7 | DRD2 1234/4885DRD3 1281/4885DRD4 1474/4885 |
| US-20090176705-A1 | MODULAR PLATFORM FOR TARGETED THERAPEUTIC DELIVERY | SIGMAR1, TMEM97, CCAR2 | DRD2 520/4885DRD3 1869/4885DRD4 1451/4885 |
| US-12611412-B2 | Targeting the TLK1/NEK1 axis in prostate cancer | NEK5, NEK3, PLK3 | DRD2 1737/4885DRD3 1355/4885DRD4 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.